Research ArticleEndocrine and Diabetes
The Novel GLP-1–Gastrin Dual Agonist ZP3022 Improves Glucose Homeostasis and Increases β-Cell Mass without Affecting Islet Number in db/db Mice
Louise S. Dalbøge, Dorthe L. C. Almholt, Trine S. R. Neerup, Niels Vrang, Jacob Jelsing and Keld Fosgerau
Journal of Pharmacology and Experimental Therapeutics August 2014, 350 (2) 353-360; DOI: https://doi.org/10.1124/jpet.114.215293
Louise S. Dalbøge
Gubra ApS, Hørsholm, Denmark (L.S.D., N.V., J.J.); and Zealand Pharma A/S, Glostrup, Denmark (D.L.C.A., T.S.R.N., K.F.)
Dorthe L. C. Almholt
Gubra ApS, Hørsholm, Denmark (L.S.D., N.V., J.J.); and Zealand Pharma A/S, Glostrup, Denmark (D.L.C.A., T.S.R.N., K.F.)
Trine S. R. Neerup
Gubra ApS, Hørsholm, Denmark (L.S.D., N.V., J.J.); and Zealand Pharma A/S, Glostrup, Denmark (D.L.C.A., T.S.R.N., K.F.)
Niels Vrang
Gubra ApS, Hørsholm, Denmark (L.S.D., N.V., J.J.); and Zealand Pharma A/S, Glostrup, Denmark (D.L.C.A., T.S.R.N., K.F.)
Jacob Jelsing
Gubra ApS, Hørsholm, Denmark (L.S.D., N.V., J.J.); and Zealand Pharma A/S, Glostrup, Denmark (D.L.C.A., T.S.R.N., K.F.)
Keld Fosgerau
Gubra ApS, Hørsholm, Denmark (L.S.D., N.V., J.J.); and Zealand Pharma A/S, Glostrup, Denmark (D.L.C.A., T.S.R.N., K.F.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleEndocrine and Diabetes
GLP-1–Gastrin Dual Agonism Increases β-Cell Mass
Louise S. Dalbøge, Dorthe L. C. Almholt, Trine S. R. Neerup, Niels Vrang, Jacob Jelsing and Keld Fosgerau
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 353-360; DOI: https://doi.org/10.1124/jpet.114.215293
Research ArticleEndocrine and Diabetes
GLP-1–Gastrin Dual Agonism Increases β-Cell Mass
Louise S. Dalbøge, Dorthe L. C. Almholt, Trine S. R. Neerup, Niels Vrang, Jacob Jelsing and Keld Fosgerau
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 353-360; DOI: https://doi.org/10.1124/jpet.114.215293
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement